Sonotarg Limited Secures £374.7k to Advance Targeted Cancer Therapies, Reaching £20.2m Valuation

Belfast-based biotechnology firm Sonotarg Limited, a pioneer in innovative microbubble and ultrasound technologies for cancer treatment, has successfully closed a new funding round, raising £374.7k. The latest capital injection values the company at an estimated post-money valuation of £20.2m. This round saw its shares allotted on 2 April 2026, with the filing date recorded as 21 April 2026.

Founded on 23 October 2018, Sonotarg Limited is dedicated to revolutionising cancer therapy through its unique approach. The company's core offering combines sonodynamic therapy and chemotherapy, precisely targeting difficult-to-treat solid tumours, such as metastatic pancreatic cancer. This method aims to significantly improve treatment outcomes while concurrently minimising the severe side effects often associated with conventional chemotherapy. The technology underpinning Sonotarg's innovations is the result of collaborative research co-developed between the Universities of Ulster and Oxford, alongside close cooperation with leading clinicians at Belfast Hospitals.

Currently, Sonotarg Limited operates with a team of 10 employees, reflecting a focused and specialised workforce dedicated to advancing its therapeutic solutions. The company's specialities include ultrasound, ultrasound therapy, drug delivery, cancer therapy, and microbubbles, all integral to its mission of targeted cancer treatment.

This recent funding round marks another step in Sonotarg's growth trajectory. The £374.7k raised contributes to a series of funding activities that have steadily increased the company's valuation. Prior to this, Sonotarg secured £200k on 6 January 2026, at a valuation of £19.8m. Looking further back, the company raised £989.6k on 23 October 2024, and £493.1k on 6 December 2023, which valued the company at £5.5m. An earlier round on 5 April 2022 saw £1.1m raised at a valuation of £1.7m. The consistent increase in valuation across these rounds underscores investor confidence in Sonotarg's technology and its potential impact on cancer treatment.

The UK biotech sector experienced a challenging financing environment in 2025, with equity financing securing £1.9 billion, a 49% decrease from 2024. Venture capital investment specifically totalled £1.8 billion, marking a 13.2% decrease year-on-year, accompanied by a reduction in deal volume. Investors became highly selective, concentrating capital on a limited number of companies. Despite this, the UK maintained its position as Europe's leading national biotech market, accounting for 30% of all European venture financing in 2025. Deal activity showed signs of acceleration towards the end of 2025, with the fourth quarter recording the highest quarterly deal count of the year, suggesting a potential widening of investor appetite heading into 2026.

Northern Ireland, where Sonotarg is based, has shown a notable increase in science and innovation funding. A report on funding from UK Research and Innovation (UKRI) indicated that Northern Ireland experienced a 43% percentage increase in investment in research projects, the largest proportional increase of any UK area between 2021-22 and 2023-24. Total investment in the region rose from £61 million to £87 million over the same period. This regional growth provides a supportive ecosystem for companies like Sonotarg. Northern Ireland's health and life sciences sector continues to expand, with local companies securing significant backing through programmes like the UK's Biomedical Catalyst, accelerating innovations in various medical fields. The region benefits from a strong, connected, and collaborative setting, with global pharmaceutical companies, academia, health organisations, and government working together to maximise research opportunities.

Sonotarg Limited's continued ability to attract funding, even in a selective investment climate, highlights the perceived value and potential of its targeted cancer therapy technology. The company's growth in valuation reflects its progress in a critical and high-potential area of medical innovation within the broader UK life sciences landscape.